Daily Respiratory Research Analysis
Maternal RSVpreF vaccination in a large phase 3 RCT showed robust protection against severe infant RSV lower respiratory tract illness through 6 months and strong maternal–neonatal antibody transfer. Nasal epithelial transcriptomics across diverse youth cohorts identified T2-high, T17-high, and dual-low asthma endotypes with distinct pathways. A drug-based, no-wash phenotypic imaging probe accurately identified EGFR-activating mutations in lung cancer tissues, potentially accelerating treatment
Summary
Maternal RSVpreF vaccination in a large phase 3 RCT showed robust protection against severe infant RSV lower respiratory tract illness through 6 months and strong maternal–neonatal antibody transfer. Nasal epithelial transcriptomics across diverse youth cohorts identified T2-high, T17-high, and dual-low asthma endotypes with distinct pathways. A drug-based, no-wash phenotypic imaging probe accurately identified EGFR-activating mutations in lung cancer tissues, potentially accelerating treatment decisions beyond DNA sequencing.
Research Themes
- RSV prevention via maternal immunization
- Asthma endotyping using nasal epithelial transcriptomics
- Phenotypic diagnostics for EGFR mutations in lung cancer
Selected Articles
1. Image-Based Phenotypic Profiling Enables Rapid and Accurate Assessment of EGFR-Activating Mutations in Tissues from Lung Cancer Patients.
A covalent, quenched TKI-derived probe enables no-wash, real-time imaging of mutant EGFR, distinguishing mutant from wild-type tumors in vivo and predicting EGFR mutations in patient tissues with 94% accuracy (98% with IHC). This phenotypic imaging approach complements or accelerates DNA-based testing and may streamline EGFR-TKI decision-making.
Impact: Introduces a practical, high-accuracy phenotypic diagnostic that could shorten turnaround time and integrate functional protein-level readouts into lung cancer care.
Clinical Implications: If validated prospectively, this probe could complement or, in some settings, precede sequencing to rapidly stratify patients for EGFR-TKI therapy from biopsy material, especially when tissue is limited or turnaround time is critical.
Key Findings
- Designed a covalent, quenched EGFR-TKI probe enabling no-wash real-time imaging of EGFR in living cells.
- Distinguished EGFR-mutant from wild-type tumors in mice via fluorescence intensity with high contrast.
- Predicted EGFR mutations in patient tumor tissues with 94% accuracy; 98% when integrated with IHC.
Methodological Strengths
- Rational probe design enabling covalent, specific engagement of EGFR kinase with no-wash imaging.
- Validation across systems: living cells, murine models, and human tumor biopsies with quantitative accuracy.
Limitations
- Clinical validation sample size not specified and likely limited; prospective, multicenter studies are needed.
- May not capture rare/complex EGFR alterations or co-mutations; requires viable tissue and imaging infrastructure.
Future Directions: Prospective head-to-head comparisons with NGS in diverse cohorts; expansion to resistance mutations and other oncogenic kinases; workflow integration for real-world turnaround and cost-effectiveness.
Determining mutations in the kinase domain of the epidermal growth factor receptor (EGFR) is critical for the effectiveness of EGFR tyrosine kinase inhibitors (TKIs) in lung cancer. Yet, DNA-based sequencing analysis of tumor samples is time-consuming and only provides gene mutation information on EGFR, making it challenging to design effective EGFR-TKI therapeutic strategies. Here, we present a new image-based method involving the rational design of a quenched probe based on EGFR-TKI to identify mutant proteins, which permits specific and "no-wash" real-time imaging of EGFR in living cells only upon covalent targeting of the EGFR kinase. We also show that the probe enables distinguishing EGFR mutant tumor-bearing mice from wild-type tumor-bearing mice via fluorescence-intensity-based imaging with high signal contrast. More interestingly, the image-based phenotypic approach can be used to predict EGFR mutations in tumors from lung cancer patients with an accuracy of 94%. Notably, when immunohistochemistry analysis is integrated, an improved accuracy of 98% is achieved. These data delineate a drug-based phenotypic imaging approach for in-biopsy visualization and define functional groups of EGFR mutants that can effectively guide EGFR-TKI therapeutic decision-making besides gene mutation analysis.
2. Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial.
In this global phase 3 RCT of 7,420 pregnant participants, maternal RSVpreF vaccination reduced severe, medically attended infant RSV lower respiratory tract illness by 82.4% at 90 days and 70.0% at 180 days post birth. The vaccine elicited robust maternal responses and efficient antibody transfer to newborns with no new safety signals.
Impact: Provides definitive, large-scale randomized evidence supporting maternal RSV immunization to protect infants through 6 months, addressing a major global respiratory burden.
Clinical Implications: Supports widespread implementation of maternal RSVpreF vaccination to prevent severe infant RSV illness up to 6 months, with strong maternal–neonatal immunogenicity and reassuring safety.
Key Findings
- Vaccine efficacy against severe, medically attended infant RSV LRTI was 82.4% (90 days) and 70.0% (180 days).
- Robust maternal immune responses with highly efficient transplacental transfer across multiple subgroups.
- Final safety profile remained consistent with primary analysis with no new safety concerns.
Methodological Strengths
- Phase 3 randomized, double-blind, placebo-controlled, multinational design with large sample size.
- Prespecified clinical endpoints and registered protocol; included immunogenicity subset for mechanistic insight.
Limitations
- Efficacy reported through 180 days; longer-term infant outcomes were not assessed.
- Immunogenicity assessed in a subset; regional heterogeneity in outcomes requires continued monitoring (addressed in companion analyses).
Future Directions: Assess durability beyond 6 months, co-administration strategies, real-world effectiveness across regions, and integration with infant monoclonal prevention programs.
OBJECTIVE: To evaluate descriptive efficacy data, exploratory immunogenicity data, and safety follow-up through study completion from the global, phase 3 MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal vaccination trial of bivalent respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVpreF). METHODS: MATISSE was a phase 3, randomized, double-blinded, placebo-controlled trial. Healthy pregnant participants aged 49 years or younger at 24-36 weeks of gestation were randomized (1:1) to receive a single RSVpreF 120 micrograms or placebo dose. Primary efficacy endpoints included newborn and infant severe RSV-associated medically attended lower respiratory tract illness within 180 days after birth. The RSV-A and RSV-B serum neutralizing antibody titers were determined in a subset of pregnant participants and their newborns. RESULTS: In this final analysis, 7,420 pregnant participants were randomized, and 7,307 children were born (RSVpreF n=3,660, placebo n=3,647). Vaccine efficacy , defined as protection against newborn and infant severe RSV-associated medically attended lower respiratory tract illness, was 82.4% (95% CI, 57.5-93.9) and 70.0% (95% CI, 50.6-82.5) within 90 and 180 days of birth, respectively. The RSVpreF induced robust immune responses in pregnant participants and resulted in highly efficient transfer of maternal antibodies to their newborns across subgroups (by gestational age at delivery and at vaccination, number of days from vaccination to delivery, country, maternal age). Final RSVpreF safety results in pregnant and newborn and infant participants were consistent with the primary analysis with no new safety concerns identified. CONCLUSION: This final analysis of MATISSE trial data confirms the primary analysis conclusions: Maternal vaccination with RSVpreF has a favorable safety profile in both pregnant and newborn and infant participants and demonstrates efficacy against RSV-associated lower respiratory tract illness in infants through age 6 months. The RSVpreF induces robust immune responses in pregnant individuals, with corresponding high RSV-neutralizing titers in their newborns. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov , NCT04424316.
3. Transcriptomic Profiles in Nasal Epithelium and Asthma Endotypes in Youth.
Across three youth asthma cohorts (total N≈459), nasal epithelial transcriptomics reproducibly identified T2-high, T17-high, and T2low/T17low endotypes. T2-high showed higher IgE/eosinophils and IL-13 pathway enrichment, while T17-high showed IL-17/neutrophil signaling—implicating non–T2 pathways in a large fraction of youth asthma.
Impact: Provides a scalable, minimally invasive molecular stratification for youth asthma and highlights T17-driven biology that may inform targeted therapies beyond type 2 inflammation.
Clinical Implications: Nasal transcriptomic profiling could guide endotype-based therapy selection in youth, including consideration of non–type 2 targets (e.g., IL-17/neutrophil pathways) where T2 biomarkers are low.
Key Findings
- Identified three reproducible nasal transcriptomic endotypes: T2HIGH, T17HIGH, and T2LOW/T17LOW across three cohorts.
- T2HIGH showed higher total IgE (≈584–869 IU/mL) and eosinophils (≈343–560 cells/mL) vs T2-low profiles.
- Differential expression meta-analysis: 3516 DEGs (T2HIGH) linked to IL-13 signaling; 2494 DEGs (T17HIGH) linked to IL-17/neutrophil pathways.
Methodological Strengths
- Multi-cohort analysis with consistent profiling methods and cross-cohort replication.
- Integrated clinical and immunologic correlates (IgE, eosinophils, lung function) with pathway analyses.
Limitations
- Cross-sectional design limits causal inference and prediction of treatment response.
- Cohorts enriched for Puerto Rican and Black/African American youths may require validation in broader populations.
Future Directions: Prospective studies linking nasal endotypes to biologic response, exacerbation risk, and longitudinal stability; development of clinical assays for scalable implementation.
IMPORTANCE: T helper 2 (T2) cells and T helper 17 (T17) cells are CD4+ T cell subtypes involved in asthma. Characterizing asthma endotypes based on these cell types in diverse groups is important for developing effective therapies for youths with asthma. OBJECTIVE: To identify asthma endotypes in school-aged youths aged 6 to 20 years by examining the distribution and characteristics of transcriptomic profiles in nasal epithelium. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional analysis of nasal epithelial samples from 3 studies of youths with asthma aged 6 to 20 years: Stress and Treatment Response in Puerto Rican and African American Children with Asthma (STAR; N = 156), Epigenetic Variation and Childhood Asthma in Puerto Ricans (EVA-PR; N = 237), and Vitamin D Kids Asthma (VDKA; N = 66). MAIN OUTCOMES AND MEASURES: The primary outcome was nasal epithelial transcription profiles of 3 T2 and 5 T17 pathway genes. Clinical characteristics, total and allergen-specific immunoglobulin E (IgE), blood eosinophils, and lung function were compared across profiles in all studies. RESULTS: Mean ages for STAR, EVA-PR, and VDKA participants were 14.2, 15.4, and 10.3 years, respectively. The percentage of female participants ranged from 41% to 53.2% across studies. The predominant race or ethnicity was Puerto Rican in EVA-PR (100%) and Black or African American in STAR (71.8%) and VDKA (57.6%). Three transcriptomic profiles were identified: high T2 expression (T2HIGH), high T17 expression (T17HIGH), and low expression of both pathways (T2LOW/T17LOW). Across studies, T2HIGH was present in 23% to 29% of participants, T17HIGH in 35% to 47%, and T2LOW/T17LOW in 30% to 38%. In each study, median total IgE and blood eosinophils for the T2HIGH profile was higher than for the T2LOW profiles (IgE, 584-869 vs 105-382 IU/mL; eosinophils, 343-560 vs 164-413 cells/mL). Of the participants in all profiles, at least 50% had 1 or more positive allergen-specific IgEs. A differential expression meta-analysis identified 3516 and 2494 differentially expressed genes for the T2HIGH and T17HIGH profiles, respectively. The T17HIGH profile was associated with interleukin 17 and neutrophil signaling pathways and the T2HIGH profile was associated with interleukin 13 signaling pathways. CONCLUSIONS AND RELEVANCE: Nasal transcriptomic profiles consistent with T2-high, T17-high, and T2-low/T17-low endotypes occurred in similar proportions across 3 studies of predominantly racially and ethnically minoritized youths with asthma. Most participants had T2-low asthma endotypes and sensitization to 1 or more allergens was common among these endotypes.